https://orcid.org/0000-0003-0040-5908
References
- Dang CV, Semenza GL. Oncogenic alterations of metabolism. Trends Biochem Sci. 1999;24(2):68–72.
- Semenza GL. Hypoxia-inducible factor 1 and cancer pathogenesis. IUBMB Life. 2008;60(9):591–597.
- Zhou S, Wang S, Wu Q, et al. Expression of glucose transporter-1 and -3 in the head and neck carcinoma-the correlation of the expression with the biological behaviors. ORL J Otorhinolaryngol Relat Spec. 2008;70(3):189–194.
- Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9(6):669–676.
- Denhart BC, Guidi AJ, Tognazzi K, et al. Vascular permeability factor/vascular endothelial growth factor and its receptors in oral and laryngeal squamous cell carcinoma and dysplasia. Lab Invest. 1997;77(6):659–664.
- Dong P, Li X, Yu Z, et al. Expression of cyclooxygenase-2, vascular endothelial growth factor and matrix metalloproteinase-2 in patients with primary laryngeal carcinoma: a tissue microarray study. J Laryngol Otol. 2007;121(12):1177–1183.
- Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003;3(6):401–410.
- Zambrano A, Molt M, Uribe E, et al. GLUT1 in cancer cells and the inhibitory action of resveratrol as a potential therapeutic strategy. IJMS. 2019;20(13):3374.
- Upadhyay M, Samal J, Kandpal M, et al. The Warburg effect: insights from the past decade. Pharmacol Ther. 2013;137(3):318–330.
- Starska K, Forma E, Jóźwiak P, et al. Gene and protein expression of glucose transporter 1 and glucose transporter 3 in human laryngeal cancer-the relationship with regulatory hypoxia-inducible factor-1α expression, tumor invasiveness, and patient prognosis. Tumour Biol. 2015;36(4):2309–2321.
- Cabanillas R, Rodrigo JP, Secades P, et al. The relation between hypoxia-inducible factor (HIF)-1alpha expression with p53 expression and outcome in surgically treated supraglottic laryngeal cancer. J Surg Oncol. 2009;99(6):373–378.
- Jaakkola P, Mole DR, Tian YM, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001;292(5516):468–472.
- Braakhuis BJ, Tabor MP, Kummer JA, et al. A genetic explanation of slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res. 2003;63(8):1727–1730.
- Wu XH, Lu YF, Hu XD, et al. Expression of hypoxia inducible factor-1α and its significance in laryngeal carcinoma. J Int Med Res. 2010;38(6):2040–2046.
- Cao D, Hou M, Guan YS, et al. Expression of HIF-1alpha and VEGF in colorectal cancer: association with clinical outcomes and prognostic implications. BMC Cancer. 2009;9(1):432.
- Ayala FR, Rocha RM, Carvalho KC, et al. GLUT1 and GLUT3 as potential prognostic markers for oral squamous cell carcinoma. Molecules. 2010;15(4):2374–2387. 1
- Zuo J, Wen J, Lei M, et al. Hypoxia promotes the invasion and metastasis of laryngeal cancer cells via EMT. Med Oncol. 2016;33(2):15.
- Neuchrist C, Quint C, Pammer A, et al. Vascular endothelial growth factor (VEGF) and microvessel density in squamous cell carcinomas of the larynx: an immunohistochemical study. Acta Otolaryngol. 1999;119(6):732–738.
- Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004;25(4):581–611.
- Ferrier CM, de Witte HH, Straatman H, et al. Comparison of immunohistochemistry with immunoassay (ELISA) for the detection of components of the plasminogen activation system in human tumour tissue. Br J Cancer. 1999;79(9-10):1534–1541.